MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Gossamer Bio Inc

Suletud

SektorTervishoid

1.69 -0.59

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.67

Max

1.89

Põhinäitajad

By Trading Economics

Sissetulek

-3.6M

-37M

Müük

510K

9.9M

Kasumimarginaal

-370.492

Töötajad

144

EBITDA

-1.9M

-34M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+438.01% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. aug 2025

Turustatistika

By TradingEconomics

Turukapital

98M

348M

Eelmine avamishind

2.28

Eelmine sulgemishind

1.69

Uudiste sentiment

By Acuity

50%

50%

169 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. juuli 2025, 23:34 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens Consent Orders for Proposed Acquisitions from Exxon Mobil, Chevron

17. juuli 2025, 21:14 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1 Billion Bitcoin Purchase on Hold

17. juuli 2025, 21:04 UTC

Suurimad hinnamuutused turgudel
Omandamised, ülevõtmised, äriostud

Norfolk Southern Shares Rise on WSJ Report of Union Pacific Acquisition Interest

17. juuli 2025, 23:43 UTC

Market Talk

Gold Edges Higher on Possible Position Adjustments -- Market Talk

17. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Rise on Signs of U.S. Econ Strength -- Market Talk

17. juuli 2025, 22:47 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions for Former Pioneer CEO Scott Sheffield Would Damage FTC's Credibility

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

Potential Rail Merger Could Prompt Berkshire Hathaway to Bid for CSX -- Barrons.com

17. juuli 2025, 22:46 UTC

Omandamised, ülevõtmised, äriostud

FTC Also Says Exxon Order Disregarded Guidelines and Precedent

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Maintaining Restrictions on John Hess's Employment Would 'Damage the FTC's Credibility'

17. juuli 2025, 22:43 UTC

Omandamised, ülevõtmised, äriostud

FTC: Chevron Order Disregarded FTC Merger Guidelines and Decades of Precedent

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:40 UTC

Omandamised, ülevõtmised, äriostud

FTC Reopens and Sets Aside Chevron-Hess and Exxon-Pioneer Final Consent Orders

17. juuli 2025, 22:30 UTC

Market Talk
Tulu

Netflix Sticks to Its Playbook as Competitive Landscape Changes -- Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

17. juuli 2025, 22:20 UTC

Market Talk
Tulu

Netflix Focusing Resources on TV Viewers It Hasn't Yet Captured -- Market Talk

17. juuli 2025, 22:04 UTC

Market Talk
Tulu

Netflix Redesign Done to Match Current Capabilities -- Market Talk

17. juuli 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

China Threatens to Block Panama Ports Deal Unless Its Shipping Giant Is Part of It -- 2nd Update

17. juuli 2025, 21:58 UTC

Market Talk
Tulu

Netflix Internal Data Doesn't Indicate Weaker Consumer Sentiment -- Market Talk

17. juuli 2025, 21:57 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:47 UTC

Tulu

Netflix Raises Revenue, Margin Forecasts After Strong Second Quarter -- Update

17. juuli 2025, 21:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. juuli 2025, 21:45 UTC

Market Talk

Crypto Bills Welcomed by Venture Capital, Trade Group Says -- Market Talk

17. juuli 2025, 21:38 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- 2nd Update

17. juuli 2025, 21:22 UTC

Omandamised, ülevõtmised, äriostud

Update: Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 21:05 UTC

Tulu

Netflix Earnings Soar Past Expectations. How a Weak Dollar Helped Boost Results. -- Barrons.com

17. juuli 2025, 21:04 UTC

Omandamised, ülevõtmised, äriostud

Railroad Operator Union Pacific Exploring Deal for Norfolk Southern -- Update

17. juuli 2025, 21:02 UTC

Omandamised, ülevõtmised, äriostud

Union Pacific Considering a Norfolk Southern Buyout: Report. -- Barrons.com

17. juuli 2025, 20:59 UTC

Omandamised, ülevõtmised, äriostud

Basel Medical Group Puts $1B Bitcoin Purchase on Hold

17. juuli 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

17. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

438.01% tõus

12 kuu keskmine prognoos

Keskmine 9.2 USD  438.01%

Kõrge 15 USD

Madal 4 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

6

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

169 / 376 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.